TVM Kan-do bet

TVM Capital is betting there is room in the diabetes armamentarium for a better oral insulin sensitizer and has provided newco Kaneq Bioscience Ltd. with an undisclosed sum to achieve human proof of concept with a preclinical small molecule inhibitor of protein tyrosine phosphatase 1B.